Health System Integration and Equity in Type 2 Diabetes Prevention: A Comparative Policy Analysis of Seven National Guidelines

ABSTRACT Rationale Type 2 diabetes mellitus affects more than 500 million adults worldwide, yet up to 80% of related complications are preventable through evidence‐based care. Clinical practice guidelines function as key prevention policy instruments; however, their implementation and integration into health systems vary substantially, with important implications for prevention access and health equity. Aims and Objectives This study aimed to examine how national policy integration architecture within diabetes management guidelines influences access to preventive care and health equity across diverse health system contexts. Methods A comparative qualitative policy analysis evaluated national diabetes management guidelines from seven countries (United States, United Kingdom, Japan, India, Ghana, Colombia, Australia) using the Health Policy Triangle and Integration Continuum Framework. Guidelines were scored on integration strength (1 to 5 scale) across clinical, financial and administrative domains. Equity analysis examined financing barriers, workforce distribution and cultural adaptations. Inter‐rater reliability testing achieved substantial agreement (Cohen's kappa 0.68). Results All guidelines converged on evidence‐based clinical content, yet integration scores varied threefold (range 2 to 5). High‐integration systems (United Kingdom, Australia; scores 5) achieved prevention medication access rates exceeding 80% among eligible populations through unified financing and zero cost‐sharing. Partial‐integration systems (United States, India, Ghana; scores 2 to 3) showed 30% to 50% access despite comparable clinical recommendations. Integration strength correlated strongly with implementation effectiveness (Spearman ρ  = 0.89, p  < 0.01). Financing structure emerged as the primary equity determinant. Countries with fragmented payment systems preserved disparities despite equity language in guidelines. Conclusions Preventing diabetes complications at scale requires integrated health systems where financing, workforce, and monitoring align with guideline intent. Policy priorities should emphasise unified financing, elimination of cost‐sharing for preventive therapies, and mandatory equity monitoring in quality frameworks.